Mercury Bio, Inc.
Mercury Bio is a biotechnology company focused on developing next-generation biomolecular drug delivery platforms. Sparked by breakthroughs in genomic research, the company aims to deliver RNA and small-molecule drugs through highly specific cell targeting without immune reactions, reducing obstacles and risks of traditional systems. Rebranded from Spartina Biotechnologies in 2022, Mercury Bio seeks to be a messenger and translator at the cellular level, translating disease into health. Their scientific expertise spans molecular biophysics, molecular biology, microbial genetics, biochemistry, genetic & bioinformatics, computational & statistical science, and theoretical biology. They are developing technologies to change health outcomes by addressing diseases like Alzheimer's, cancer, HIV, and Huntington’s Disease, using their proprietary chimeric extracellular vesicle (yEV™) technology for targeted drug delivery. The company collaborates with research partners such as Los Alamos National Laboratory, NCGR, New Mexico Consortium, and Himed LLC. Mercury Bio has received awards including the NM Technology Readiness Grant in 2025 and the Outstanding Partnership Award in 2024 from LANL.
Industries
Nr. of Employees
small (1-50)
Mercury Bio, Inc.
Products
Chimeric extracellular vesicle-based drug delivery platform
A platform that encapsulates nucleic acids, proteins, antibodies, enzymes, and small molecules within engineered extracellular vesicles for cell-specific delivery with reduced immune activation.
Pipeline of RNA- and protein-based therapeutic candidates
A multi-candidate pipeline that packages known molecules into EV-based vectors for targeted delivery; includes multiple development-stage programs shown on the company's pipeline materials.
Chimeric extracellular vesicle-based drug delivery platform
A platform that encapsulates nucleic acids, proteins, antibodies, enzymes, and small molecules within engineered extracellular vesicles for cell-specific delivery with reduced immune activation.
Pipeline of RNA- and protein-based therapeutic candidates
A multi-candidate pipeline that packages known molecules into EV-based vectors for targeted delivery; includes multiple development-stage programs shown on the company's pipeline materials.
Services
Collaborative research and development partnerships
Joint research collaborations and strategic partnerships with national laboratories, genome centers, and academic institutions to co-develop delivery vectors and therapeutic candidates.
Collaborative research and development partnerships
Joint research collaborations and strategic partnerships with national laboratories, genome centers, and academic institutions to co-develop delivery vectors and therapeutic candidates.
Expertise Areas
- Drug delivery platform development
- Extracellular vesicle engineering
- RNA therapeutics
- Protein therapeutic delivery
Key Technologies
- Extracellular vesicle vectors
- Natural nanoparticle drug encapsulation
- mRNA delivery
- Protein and antibody delivery